Brentuximab vedotin

被引：14
作者：
机构：
来源：
Drugs in R & D | 2011年 / 11卷 / 1期
关键词：
Brentuximab-vedotin; general; Hodgkins-disease; Research-and-; development; treatment;
D O I：
10.2165/11591070-000000000-00000
中图分类号：
学科分类号：
摘要：
Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company. It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10. It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe. This review discusses the key development milestones and therapeutic trials of this drug. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码：85 / 95
页数：10
相关论文
共 36 条
[1]  
Millennium: The Takeda Oncology Company, Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35), (2009)
[2]  
Seattle Genetics Establishes Preferred Antibody-drug Conjugate Manufacturing Relationship with Albany Molecular Research, (2004)
[3]  
Seattle Genetics Launches Manufacturing Campaign with Albany Molecular Research, (2005)
[4]  
Seattle Genetics and Millennium Report Positive Data From Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed Or Refractory ALCL at ASH Annual Meeting, (2010)
[5]  
Seattle Genetics Receives Orphan Drug Designations for SGN-35 in the United States and Europe, (2009)
[6]  
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs, (2007)
[7]  
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma, (2009)
[8]  
Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-transplant Hodgkin Lymphoma, (2010)
[9]  
Seattle Genetics and Millennium Report Positive Data From Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed Or Refractory Hodgkin Lymphoma at ASH Annual Meeting, (2010)
[10]  
Seattle Genetics and Millennium Announce Positive Top-line Brentuximab Vedotin (SGN-35) Data From Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma, (2010)
1234